USA-based drug developer GTC Biotherapeutics' human antithrombin ATryn has been approved by the Food and Drug Administration for the prevention and treatment of venous thromboembolism in hereditary antithrombin-deficient patients undergoing surgery or childbirth.
Framingham, Massachusetts-based GTC predicts Atryn could earn as much as $50.0 million in annual US sales in its first five years on the market. On the day the agent was approved, January 6, shares in the firm rose just 1% to $0.83 cents in early afternoon trading.
Hereditary antithrombin deficiency is estimated to affect one in 2,000 to one in 5,000 people, half of whom may experience a thrombosis before reaching 25 years of age and, based on a study, up to 85% may suffer a thromboembolic event by age 50.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze